Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial to Assess the Safety and Immunogenicity of the Malaria Vaccine Candidate RH5.1 Soluble Protein in Matrix-MTM Using Two Dosing Regimens

NCT06141057 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT06141057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06141057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial to Assess the Safety and Immunogenicity of the Malaria Vaccine Candidate RH5.1 Soluble Protein in Matrix-MTM Using Two Dosing Regimens
Lead sponsor
University of Oxford
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 6, 2023
Completion date
July 31, 2025
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infections, malaria, malaria,falciparum, parasitic disease, protozoan infections, vector borne diseases